Ergoteles’s Roivant Sciences ROIV Stock Holding History

Ergoteles’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-37,600	Closed	-$121K	–	1811
2022 Q3	$121K	Sell	37,600 -166,084	-82%	-$643K	﹤0.01%	1324
2022 Q2	$829K	Buy	+203,684	New	+$809K	0.02%	624

Other funds holding ROIV

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PSC

Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

Ergoteles's ROIV Position: Q4 2022 in Review

Ergoteles sold out of Roivant Sciences (ROIV) in Q4 2022, closing a stake of 37,600 shares — an estimated $121K sold.

Ergoteles first reported a position in ROIV in Q2 2022 and held it in 2 quarters. The position peaked at $829K in Q2 2022. 110 funds tracked by Wall St. Rank hold ROIV as of Q4 2022.

Ergoteles reported no remaining Roivant Sciences position as of Q4 2022 after selling out during the quarter.
Ergoteles sold 37,600 Roivant Sciences shares in Q4 2022, an estimated $121K.
Ergoteles first reported a position in Roivant Sciences in Q2 2022 and held it in 2 quarters.
Ergoteles's Roivant Sciences position peaked at $829K in Q2 2022.
110 funds tracked by Wall St. Rank held Roivant Sciences as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.